文献速递脑血管病

不明来源栓塞性卒中患者大出血的频率与预测因素:NAVIGATE-ESUS 试验

Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
PubMed 文献 · Stroke · 2020-06-10

该研究为 NAVIGATE-ESUS 随机试验的探索性分析,纳入 7213 例近期不明来源栓塞性卒中患者,比较利伐沙班 15 mg 每日一次与阿司匹林 100 mg 每日一次。中位随访 11 个月期间发生 85 例大出血,最常见部位为胃肠道(38%),其次为颅内(29%)。利伐沙班分组、东亚地区、收缩压≥160 mm Hg 及肾功能受损为独立预测因素。

要点

  • 利伐沙班组大出血风险高于阿司匹林组(HR 2.7,95%CI 1.7-4.3)。
  • 东亚地区与颅内出血风险显著相关(HR 6.3,95%CI 2.2-18.0)。
  • 收缩压≥160 mm Hg 和肾功能受损亦为独立预测因素。

核心结论

  • 不明来源栓塞性卒中患者中,利伐沙班分组、东亚地区、收缩压升高及肾功能受损是大出血的独立预测因素。
  • 东亚地区与颅内出血风险强烈相关,估计肾小球滤过率应考虑用于出血风险分层。

研究设计与样本

  • 国际多中心随机试验 NAVIGATE-ESUS 的探索性分析,纳入 7213 例近期不明来源栓塞性卒中患者。
  • 比较利伐沙班 15 mg 每日一次与阿司匹林 100 mg 每日一次,大出血采用国际血栓与止血学会标准定义。

主要发现

  • 中位随访 11 个月期间共发生 85 例大出血,最常见部位为胃肠道(38%),其次为颅内(29%)。
  • 利伐沙班分组(HR 2.7,95%CI 1.7-4.3)、东亚地区(HR 2.5,95%CI 1.6-3.9)、收缩压≥160 mm Hg(HR 2.2,95%CI 1.2-3.8)及估计肾小球滤过率每降低 10 mL/min/1.73 m2(HR 1.2,95%CI 1.0-1.3)与发生大出血独立相关。
  • 5 例(6%)大出血为致命性;15 例脑出血中 2 例(13%)为致命性。
  • 未发现利伐沙班起始后存在早期高风险期。
  • 东亚参与者脑出血年化发生率为 0.67%,其他地区为 0.11%(HR 6.3,95%CI 2.2-18.0)。

临床怎么用

  • 对不明来源栓塞性卒中患者启动抗凝前应评估收缩压及估计肾小球滤过率以分层出血风险。
  • 东亚地区患者使用利伐沙班时需特别关注颅内出血风险。
  • 利伐沙班治疗期间未观察到早期高风险期,但大出血仍以胃肠道和颅内为主。

局限性

  • 为大出血的探索性分析,非预设主要终点。
  • 中位随访仅 11 个月,事件数有限(85 例大出血)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Risks, sites, and predictors of major bleeding during antithrombotic therapies have not been well defined for patients with recent embolic stroke of undetermined source. METHODS: Exploratory analysis of major bleeds defined by International Society of Thrombosis and Hemostasis criteria occurring among 7213 participants in international NAVIGATE (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial) embolic stroke of undetermined source randomized trial comparing rivaroxaban 15 mg daily with aspirin 100 mg daily. RESULTS: During a median follow-up of 11 months, 85 major bleeds occurred. The most frequent site was gastrointestinal (38%), followed by intracranial (29%). Assignment to rivaroxaban (hazard ratio [HR], 2.7 [95% CI, 1.7-4.3]), East Asia region (HR, 2.5 [95% CI, 1.6-3.9]), systolic blood pressure ≥160 mm Hg (HR, 2.2 [95% CI, 1.2-3.8]), and reduced estimated glomerular filtration rate (HR, 1.2 per 10 mL/min per 1.73 m2 decrease, [95% CI, 1.0-1.3]) were independently associated with presence of major bleeds. Five (6%) were fatal. Among 15 patients with intracerebral hemorrhage, 2 (13%) were fatal. There was no evidence of an early high-risk period following initiation of rivaroxaban. The annualized rate of intracerebral hemorrhage was 6-fold higher among East Asian participants (0.67%) versus all other regions (0.11%; HR, 6.3 [95% CI, 2.2-18.0]). Distribution of bleeding sites was similar for rivaroxaban and aspirin. CONCLUSIONS: Among embolic stroke of undetermined source patients participating in an international randomized trial, independent predictors of major bleeding were assignment to rivaroxaban, East Asia region, increased systolic blood pressure, and impaired renal function. East Asia as a region was strongly associated with risk of intracerebral hemorrhage. Estimated glomerular filtration rate should be a consideration for stratifying bleeding risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mikulík R, Eckstein J, Pearce LA, et al. Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. Stroke. 2020. PMID: 32517582. doi:10.1161/STROKEAHA.119.027995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。